Portalvein reconstruction with a cadaveric descending thoracic aortic homograft.

Publication/Presentation Date

6-1-2022

Abstract

Improvements in chemoradiotherapy have rendered complex pancreatic cancers involving the portal vein (PV) amenable to resection. PV reconstruction (PVR) is an essential component. Various conduits have been proposed; however, the optimal choice remains unknown. Fourteen patients underwent PVR with a cadaveric descending thoracic aortic homograft from 2014 to 2020. The primary diagnosis was pancreatic cancer. The splenic vein was ligated in seven patients (50%). The 30-day and 3-, 12-, and 24-month primary patency rates were 100%, 86%, 76%, and 76%, respectively. We found a cadaveric descending thoracic aortic homograft is an excellent conduit for PVR, given the optimal size, rapidly availability, favorable risk profile, and absence of harvest site complications.

Volume

8

Issue

2

First Page

294

Last Page

297

ISSN

2468-4287

Disciplines

Medicine and Health Sciences

PubMedID

35647419

Department(s)

Department of Medicine, Cardiology Division

Document Type

Article

Share

COinS